Ann Rheum Dis:银屑病关节炎中患者评估和医生评估的缓解和低疾病活动性的比较

2018-11-16 xiangting MedSci原创

VLDA/MDA比基于DAPSA的缓解/LDA更为严格。

这项研究目的是根据患者和医生的观点,比较银屑病关节炎(PsA)患者缓解和低疾病活动性(LDA)的不同定义。

在ReFlap试验中(PsA的缓解/急性发作;NCT03119805),纳入14个国家经医生确诊且病程>2年的成年PsA患者。缓解定义为疾病活动性非常低(VLDA)、银屑病关节炎疾病活动指数(DAPSA)≤4、医生感知和患者感知的缓解(具体问题是/否)。LDA定义为最小疾病活动性(MDA)、DAPSA<14,以及医生感知和患者感知的LDA。通过横断面评估将这些定义的频率、一致性(患病率调整的kappa)、敏感性和特异性与患者定义的状态进行比较。

410例患者中,平均年龄(SD)为53.9(12.5)岁,50.7%为男性,病程为11.2(8.2)年,56.8%的患者使用生物制剂,经常达到缓解/LDA: 分别为缓解从12.4%(VLDA)至36.1%(医生感知的缓解),LDA从25.4%(MDA)至43.9%(患者感知的LDA)。因此,患者感知的缓解/ LDA较频繁(65.4%)。患者感知的缓解/LDA与综合评分之间的一致性为中等至良好(kappa范围,0.12-0.65)。当使用患者感知的缓解或LDA状态作为参考时,DAPSA定义的缓解/LDA和VLDA/MDA的敏感性分别为73.1%和51.5%,特异性分别为76.8%和88.0%。使用单一问题的医生感知的缓解/LDA较频繁(67.6%),但与其他定义比较,表现不佳。

在这个无选定的人群中,经常达到缓解/LDA。VLDA/MDA比基于DAPSA的缓解/LDA更为严格。基于DAPSA的缓解/LDA在检测患者定义的缓解或缓解/LDA方面优于VLDA/MDA。未来需要关于长期结局的进一步研究。

原始出处:

Clémence Gorlier. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Ann Rheum Dis. 15 November 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690852, encodeId=c38316908526c, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jan 24 17:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756064, encodeId=ead91e5606449, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Aug 22 08:03:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012856, encodeId=da3f201285635, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 09 19:03:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723951, encodeId=2b771e23951e9, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Jan 13 02:03:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265849, encodeId=05c812658495d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Nov 18 07:03:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690852, encodeId=c38316908526c, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jan 24 17:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756064, encodeId=ead91e5606449, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Aug 22 08:03:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012856, encodeId=da3f201285635, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 09 19:03:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723951, encodeId=2b771e23951e9, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Jan 13 02:03:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265849, encodeId=05c812658495d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Nov 18 07:03:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690852, encodeId=c38316908526c, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jan 24 17:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756064, encodeId=ead91e5606449, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Aug 22 08:03:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012856, encodeId=da3f201285635, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 09 19:03:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723951, encodeId=2b771e23951e9, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Jan 13 02:03:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265849, encodeId=05c812658495d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Nov 18 07:03:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690852, encodeId=c38316908526c, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jan 24 17:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756064, encodeId=ead91e5606449, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Aug 22 08:03:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012856, encodeId=da3f201285635, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 09 19:03:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723951, encodeId=2b771e23951e9, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Jan 13 02:03:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265849, encodeId=05c812658495d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Nov 18 07:03:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690852, encodeId=c38316908526c, content=<a href='/topic/show?id=4a49e0695f2' target=_blank style='color:#2F92EE;'>#疾病活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70695, encryptionId=4a49e0695f2, topicName=疾病活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6bf29152327, createdName=hukaixun, createdTime=Thu Jan 24 17:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756064, encodeId=ead91e5606449, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Thu Aug 22 08:03:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012856, encodeId=da3f201285635, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 09 19:03:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723951, encodeId=2b771e23951e9, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Jan 13 02:03:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265849, encodeId=05c812658495d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Nov 18 07:03:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
    2018-11-18 lmm397

相关资讯

Arthritis Rheumatol:银屑病关节炎中最小的疾病活动性能否预防亚临床动脉粥样硬化的进展

这项研究结果支持这样的建议:一旦达到MDA,理想情况下应维持较长时间,以防止PsA患者颈动脉粥样硬化和动脉硬化的进展。

J Rheumatol:银屑病关节炎患者矫形外科手术的发生率和预测因素

20%的PsA患者需要手术治疗。研究发现,尽管治疗方法有所变化,但PsA患者的预后并没有改变矫形外科手术的风险。

Ann Rheum Dis:银屑病关节炎的疾病活动性是否可通过28关节改良DAPSA进行充分评估?

这项研究表明,仅有28关节计数的数据集可用于计算DAPSA28,特别是低疾病活动性的患者。

J Rheumatol:妊娠对银屑病关节炎患者疾病活动性的影响

继续生物制剂治疗与妊娠期间疾病活动性水平低、急性发作可能性低相关。

J Rheumatol:银屑病关节炎中初步超声附着点炎评分的建立-GRAPPA超声工作组

这项研究确定了可以区分PsA和对照的潜在基本超声异常和附着点位点。

J Rheumatol:银屑病关节炎中不同缓解和低疾病活动定义的比较及其预后价值评估

对于PsA的评估,VLDA和MDA定义比DAPSA和cDAPSA定义更严格。